EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

The evolution of cancer therapeutics: from “undruggable” to “drugged”

Daniel Neureiter iD, Matthias Ocker iD

Translational Cancer Research · 2026-07 · 15 (7) · 514-514

DOI: 10.21037/tcr-2026-0807 ↗

Kurz gefasst

Editorial in der Zeitschrift Translational Cancer Research, 2026-07. Verfasst von Daniel Neureiter und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Paracelsus Medical University/University Hospital Salzburg (SALK), Salzburg, Austria. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Cancerdruggedtargetstherapeuticsundruggable

Autor:innen und Institutionen

  • Institute of Pathology, Paracelsus Medical University/University Hospital Salzburg (SALK), Salzburg, Austria.
  • Cancer Cluster Salzburg, Salzburg, Austria.
  • Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Campus Charité Mitte, Charité University Medicine Berlin, Berlin, Germany.
  • EO Translational Insights Consulting GmbH, Berlin, Germany.
  • Tacalyx GmbH, Berlin, Germany.

ORCID-Profile: Daniel Neureiter, Matthias Ocker

Zitieren

APA

Neureiter, D., & Ocker, M. (2026). The evolution of cancer therapeutics: from “undruggable” to “drugged”. Translational Cancer Research, 15(7), 514-514. https://doi.org/10.21037/tcr-2026-0807

Vancouver

Neureiter D, Ocker M. The evolution of cancer therapeutics: from “undruggable” to “drugged”. Translational Cancer Research. 2026;15(7):514-514. doi:10.21037/tcr-2026-0807

BibTeX
@article{Neureiter2026,
  author = {Neureiter, Daniel and Ocker, Matthias},
  title = {The evolution of cancer therapeutics: from “undruggable” to “drugged”},
  journal = {Translational Cancer Research},
  year = {2026},
  volume = {15},
  number = {7},
  pages = {514--514},
  doi = {10.21037/tcr-2026-0807}
}
Kostenlos starten →